Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chromosome 17 is one of the 23 pairs of human chromosomes, representing approximately 2.5% to 3% of the total cellular DNA (National Library of Medicine, 2024). It encompasses about 83 million base pairs and encodes over 1,100 genes, many of which are critical in human health and disease (National Human Genome Research Institute, 2024). Key genes located on this chromosome include the tumor suppressor TP53, the DNA repair gene BRCA1, and the oncogene ERBB2 (HER2) (PubMed, 2023). While the chromosome as a whole is not a therapeutic target, its constituent genes and their protein products are central to many drug development efforts, particularly in oncology. Structural variations such as 17p deletions or polysomy 17 serve as vital diagnostic and prognostic biomarkers in clinical practice (StatPearls, 2024). Additionally, mutations in genes like NF1 and MAPT on this chromosome are linked to neurofibromatosis and various tauopathies, respectively (UniProt, 2024). Consequently, while not a "target" in the traditional sense, its genomic integrity is fundamental to cellular homeostasis and therapeutic response.
Not applicable
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chromosome 17 (Chr17).